In vitro characterization of five humanized OKT3 effector function variant antibodies.
about
Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes caseStructural characterization of a human Fc fragment engineered for lack of effector functionsMonitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodiesImmunotherapy of type 1 diabetes: where are we and where should we be going?Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1Have we overestimated the benefit of human(ized) antibodies?Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.Enhancing SIV-specific immunity in vivo by PD-1 blockade.Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).Modulation of the human T cell response by a novel non-mitogenic anti-CD3 antibodyDevelopment of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodiesPhase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allograftsTeplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody.Achieving antigen-specific tolerance in diabetes: regulating specifically.New and future immunomodulatory therapy in type 1 diabetes.T cell-directed therapies: lessons learned and future prospects.Advancements in immune toleranceTreatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.Treating autoimmune disease by targeting CD8(+) T suppressor cellsCharacterization of a surrogate murine antibody to model anti-human CD3 therapies.Monoclonal antibody-induced cytokine-release syndrome.Optimizing therapeutic antibody function: progress with Fc domain engineering.Type 1 diabetes: etiology, immunology, and therapeutic strategies.Autoimmunity and inflammation: murine models and translational studies.In vitro cytokine release assays: reducing the risk of adverse events in man.Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1.Enhancement of antibody functions through Fc multiplications.Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF.TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ TregsNKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti-CD3 antibody.Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity.The case for an autoimmune aetiology of type 1 diabetes.Antibodies inhibit prion propagation and clear cell cultures of prion infectivity.IgG Fc engineering to modulate antibody effector functions.
P2860
Q27028100-74AA402B-93E8-48C0-B5EB-93AE9C48EC94Q27650876-75FB2F88-EDB5-48DD-B063-1C9BB4CE809CQ33637111-A9A8364D-8C42-4C8E-9206-9F2E6570B1BAQ33815506-C715E496-7142-4632-86FA-223E419668BFQ33870167-E3999221-01F8-4645-8664-C01BBA37B81FQ34142714-311ED15A-00C9-4521-8FAE-D774E9E53D68Q34375578-A958C98D-2BB8-4304-9B79-F764B8BE8BD2Q34421851-807B831F-7D0A-420E-9894-104345DAE9E8Q34601856-97E88421-81D4-4A86-B8FE-049510043DF9Q34828735-4CE31B67-A1E6-40C6-BD38-536C658E337DQ35142083-23CB55E8-07B9-483C-829D-0AC3E9055E92Q35154170-9B803F85-40F6-4DC0-B1BC-D686A895C255Q35232365-BCE5C4C7-4C3D-4022-93D4-35B5E4D7978CQ35321191-C02C3033-5959-45F5-B2AE-A683F577832EQ35610286-65E935EB-BE78-4642-ABFC-C9AFC2CAEE5FQ35833324-BA1CDDA3-01EA-462E-9D17-AA0EB03849C3Q36212815-90C65292-6E9A-4D8E-BEA1-AB4CB8FFDECEQ36327351-FC3A4B83-969D-47A2-9834-AC7CB511E41BQ36650474-5DC93805-FC2B-4A52-9FCE-250B92E4AE6FQ36688370-1992237D-A818-414D-B791-A839287EDA4AQ36988746-E54C2872-C40B-4522-A746-476D149116D6Q37327047-A0632180-A731-49C8-A947-07BACC422EBAQ37467452-F1C0EBEF-37DD-4BC7-82A2-33421FA79913Q37530206-6CABD601-BAB7-42E3-9029-753074210E62Q37755276-68A47CB5-E876-4742-8BAC-899DD15E4239Q37804830-F21DDCBA-79AA-44A2-AC9B-AC6EA8CEE9C9Q37830198-71BD7D65-9734-4601-88ED-D238CF7A45D8Q37891882-261A0E81-ACF0-4910-BA62-E61B1F888DF4Q37963914-97FE8EBA-1866-4550-8EA3-B3F4DEA8C177Q38057713-A7F9462F-5856-44D4-9E4A-C8F5F18F5432Q38187146-AB77643C-DB6B-4525-A822-E4AF9E8AD281Q38847426-EA91DD10-F6F9-4A93-8D1E-DB9C337F07D9Q40365750-D2E85965-094E-46F7-9E4B-85C5D5AC96DAQ41856268-DFE5E159-CE82-478A-A269-84ED06BF7C9DQ42181372-2D24426F-7F07-402E-9560-612023B5D6F6Q42397410-356B448D-30D7-4C43-932F-1AA764F2B702Q42544946-E0A81975-285E-472A-818F-897E5A7908DBQ44420822-5D648A75-73E7-4B67-9221-82322EAAF63CQ46161882-F1868AF5-35C0-4C6A-988E-E9515D858E5AQ47593242-03299FAB-C8CA-4E5C-834D-F5B5F4365C7F
P2860
In vitro characterization of five humanized OKT3 effector function variant antibodies.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
In vitro characterization of five humanized OKT3 effector function variant antibodies.
@en
In vitro characterization of five humanized OKT3 effector function variant antibodies.
@nl
type
label
In vitro characterization of five humanized OKT3 effector function variant antibodies.
@en
In vitro characterization of five humanized OKT3 effector function variant antibodies.
@nl
prefLabel
In vitro characterization of five humanized OKT3 effector function variant antibodies.
@en
In vitro characterization of five humanized OKT3 effector function variant antibodies.
@nl
P2093
P356
P1433
P1476
In vitro characterization of five humanized OKT3 effector function variant antibodies.
@en
P2093
Bluestone JA
Collins AM
Jolliffe LK
Rothermel AL
P356
10.1006/CIMM.2000.1617
P577
2000-02-01T00:00:00Z